The FDA's Overton era, and dispatches from Shanghai

The podcast opens with discussion of recent biotech news before focusing on two major stories. First, President Trump's nominee for FDA commissioner, Heidi Overton, appeared on Capitol Hill. Overton is a 37-year-old preventive medicine physician who worked in both Trump administrations and is close to Robert F. Kennedy Jr. on vaccine policy issues. STAT reporter Margaret Manto explains that Overton straddles conservative and MAHA movement politics but is viewed as somewhat of a moderating force—some MAHA supporters see her as obstructing their more radical policy goals, including on psychedelics. She is known for advocacy on price transparency and anti-abortion positions. Overton's nomination comes after 18 months of FDA turmoil: the agency lost 20% of its workforce (from 20,000 to 16,000 employees) due to federal budget cuts, longtime staff left citing political meddling and loss of scientific deference, and her predecessor Marty Makary faced criticism for politicizing decisions and clashing with both career scientists and President Trump. Manto suggests Overton may bring stability through her low-profile approach and team-player reputation, though concerns exist about potential action on mifepristone and telehealth abortion access. The episode also covers an emerging market opportunity: after 15-20 years of pharmaceutical company neglect, osteoporosis treatment is experiencing renewed investment interest from venture capitalists and major pharma including Eli Lilly. Additionally, T-Lix Pharmaceuticals is acquiring ITM in a $1.65 billion radiopharmaceutical deal that creates a major competitor to Novartis in targeted cancer therapies using radioactive isotopes. In the second half, Jason Mast reports from Shanghai on China's transformation into a drug discovery powerhouse. Approximately one-third of the global drug development pipeline now originates from China, and major pharma companies have spent roughly $50 billion acquiring and licensing Chinese-developed medicines. Mast describes the infrastructure boom in Shanghai's biotech district, where buildings previously owned by unsuccessful foreign pharma operations are now occupied by thriving Chinese biotechs. The efficiency advantages cited include government support, streamlined NMPA (Chinese FDA) regulations enabling faster clinical trials, a growing population of STEM graduates, and returning Chinese scientists with overseas experience. However, Mast notes that this rapid expansion has involved safety concerns: investigator-initiated trials (which allow faster early-stage studies without full central approval) have resulted in three patient deaths in gene therapy trials, prompting new Chinese government controls. Geopolitical tensions shape the industry—Chinese biotechs are establishing U.S.-investor-backed entities to facilitate sales to American pharma companies and avoid national security obstacles. Despite protectionist rhetoric from U.S. politicians, competition for molecules remains intense, with investors and pharma companies actively bidding against each other in what Mast characterizes as a "gold rush."